Coya Therapeutics To Highlight ALS Data In Poster Presentation At 2026 Annual NEALS Meeting; Co. Currently Conducts ALSTARS Trial, Phase 2/3, Study To Evaluate COYA 302 For ALS Treatment

ALS (amyotrophic lateral sclerosis) is a life-threatening neurodegenerative disease characterized by a highly variable rate of progression among affected individuals

The Company believes implementation of a prospective stratification in the ALSTARS Trial based on baseline axonal injury burden, as measured by serum neurofilament light chain (NfL) levels, balances prognostic risk across arms, reduces baseline heterogeneity, and may improve the signal-to-noise ratio for the ALSFRS-R, the primary outcome measure

Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces a poster presentation at the 2026 Annual NEALS Meeting on October 28th in Clearwater, Florida. NEALS (Network of Excellence for ALS) is the world’s largest ALS research consortium, dedicated to accelerating the development of new treatments for ALS and Motor Neuron Disease (MND).

Coya is currently conducting the ALSTARS Trial, a Phase 2/3, randomized, multi-center, double-blind, placebo-controlled study to evaluate the efficacy and safety of COYA 302 for the treatment of ALS (ClinicalTrials.gov ID: NCT07161999).